BioCryst Pharmaceuticals (BCRX) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

BioCryst Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$874.84M

Latest Revenue (Q)

$218.25M

Main Segment (Y)

Product

BioCryst Pharmaceuticals Revenue by Period

BioCryst Pharmaceuticals Revenue by Year

Date	Revenue	Change
2025-12-31	$874.84M	94.10%
2024-12-31	$450.71M	36.00%
2023-12-31	$331.41M	22.37%
2022-12-31	$270.83M	72.31%
2021-12-31	$157.17M	782.38%
2020-12-31	$17.81M	-63.53%
2019-12-31	$48.84M	136.45%
2018-12-31	$20.65M	-18.00%
2017-12-31	$25.19M	-4.43%
2016-12-31	$26.35M	-45.39%
2015-12-31	$48.26M	254.62%
2014-12-31	$13.61M	-21.48%
2013-12-31	$17.33M	-34.09%
2012-12-31	$26.29M	33.85%
2011-12-31	$19.64M	-69.07%
2010-12-31	$63.50M	-14.87%
2009-12-31	$74.59M	31.87%
2008-12-31	$56.56M	-20.60%
2007-12-31	$71.24M	1046.79%
2006-12-31	$6.21M	3990.38%
2005-12-31	$151.87K	-54.92%
2004-12-31	$336.90K	-79.38%
2003-12-31	$1.63M	-7.92%
2002-12-31	$1.77M	-84.10%
2001-12-31	$11.16M	236.52%
2000-12-31	$3.32M	32.62%
1999-12-31	$2.50M	-60.94%
1998-12-31	$6.40M	540.00%
1997-12-31	$1.00M	-62.96%
1996-12-31	$2.70M	1250.00%
1995-12-31	$200.00K	-71.43%
1994-12-31	$700.00K	-

BioCryst Pharmaceuticals generated $874.84M in revenue during NA 2025, up 94.10% compared to the previous quarter, and up 4911.50% compared to the same period a year ago.

BioCryst Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2026-06-30	$218.25M	39.53%
2026-03-31	$156.41M	-61.53%
2025-12-31	$406.56M	155.06%
2025-09-30	$159.40M	-2.42%
2025-06-30	$163.35M	12.24%
2025-03-31	$145.53M	10.64%
2024-12-31	$131.53M	12.34%
2024-09-30	$117.08M	7.09%
2024-06-30	$109.33M	17.86%
2024-03-31	$92.76M	-0.69%
2023-12-31	$93.40M	7.68%
2023-09-30	$86.74M	5.15%
2023-06-30	$82.49M	19.94%
2023-03-31	$68.78M	-13.54%
2022-12-31	$79.55M	4.90%
2022-09-30	$75.83M	15.71%
2022-06-30	$65.53M	31.27%
2022-03-31	$49.92M	5.86%
2021-12-31	$47.16M	15.04%
2021-09-30	$40.99M	-17.94%
2021-06-30	$49.96M	162.13%
2021-03-31	$19.06M	374.58%
2020-12-31	$4.02M	-34.19%
2020-09-30	$6.10M	112.54%
2020-06-30	$2.87M	-40.47%
2020-03-31	$4.82M	-87.86%
2019-12-31	$39.73M	2138.03%
2019-09-30	$1.77M	22.58%
2019-06-30	$1.45M	-75.40%
2019-03-31	$5.89M	115.72%
2018-12-31	$2.73M	87.69%
2018-09-30	$1.45M	-88.36%
2018-06-30	$12.49M	214.24%
2018-03-31	$3.98M	2.21%
2017-12-31	$3.89M	-55.59%
2017-09-30	$8.76M	182.67%
2017-06-30	$3.10M	-67.16%
2017-03-31	$9.44M	5.05%
2016-12-31	$8.98M	15.72%
2016-09-30	$7.76M	62.17%
2016-06-30	$4.79M	-0.68%
2016-03-31	$4.82M	4.74%
2015-12-31	$4.60M	-58.11%
2015-09-30	$10.99M	-57.48%
2015-06-30	$25.84M	278.58%
2015-03-31	$6.83M	25.34%
2014-12-31	$5.45M	68.19%
2014-09-30	$3.24M	120.87%
2014-06-30	$1.47M	-57.61%
2014-03-31	$3.46M	-67.28%
2013-12-31	$10.57M	342.32%
2013-09-30	$2.39M	190.99%
2013-06-30	$821.00K	-76.90%
2013-03-31	$3.55M	-13.34%
2012-12-31	$4.10M	-28.81%
2012-09-30	$5.76M	36.84%
2012-06-30	$4.21M	-65.55%
2012-03-31	$12.22M	133.94%
2011-12-31	$5.22M	-0.48%
2011-09-30	$5.25M	40.54%
2011-06-30	$3.73M	-31.28%
2011-03-31	$5.43M	-67.44%
2010-12-31	$16.69M	39.12%
2010-09-30	$12.00M	57.56%
2010-06-30	$7.62M	-70.79%
2010-03-31	$26.07M	-52.51%
2009-12-31	$54.90M	420.43%
2009-09-30	$10.55M	120.35%
2009-06-30	$4.79M	9.82%
2009-03-31	$4.36M	-87.27%
2008-12-31	$34.24M	284.98%
2008-09-30	$8.89M	234.49%
2008-06-30	$2.66M	-75.31%
2008-03-31	$10.77M	-61.78%
2007-12-31	$28.17M	-

BioCryst Pharmaceuticals generated $218.25M in revenue during Q2 2026, up 39.53% compared to the previous quarter, and up 149.96% compared to the same period a year ago.

BioCryst Pharmaceuticals Revenue Breakdown

BioCryst Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Collaborative And Other Research And Development	$7.71M	$8.04M	$6.72M	$214.00K	-
Product	$623.15M	$442.67M	$324.70M	$267.71M	-
License	$243.98M	-	-	-	-
Milestone	-	-	-	-	-
Collaborative and Other Research and Development	-	-	-	-	$5.92M

BioCryst Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (71.23%), License (27.89%), and Collaborative And Other Research And Development (0.88%).

Quarterly Revenue by Product

Product/Service	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
License and Other Revenues	$60.74M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product	$157.51M	$151.40M	$157.74M	$162.43M	$143.79M	$237.33M	$116.07M	$89.27M	$239.41M	$85.29M	$78.06M	$75.21M	$64.89M	-	-	-	-	-	-	-
Collaborative and Other Research and Development	-	$2.00M	$1.66M	$923.00K	$1.75M	$1.02M	$3.49M	$1.45M	$1.99M	$612.00K	$14.00K	$104.00K	$30.00K	$903.00K	$1.53M	$1.40M	-	-	-	-
License	-	$3.02M	$708.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Royalty	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.42M	$600.00K	$540.00K	-	-	-	-
Collaborative And Other Research And Development	-	-	-	-	-	-	-	-	-	-	-	-	-	$66.00K	-	-	-	-	-	-
Milestone Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

BioCryst Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 26: Product (72.17%), and License and Other Revenues (27.83%).

BioCryst Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
BCRX	BioCryst Pharmaceuticals	$874.84M	$218.25M
ARDX	Ardelyx	$407.32M	$120.88M
STOK	Stoke Therapeutics	$184.42M	$9.32M
WVE	Wave Life Sciences	$42.73M	$2.27M
UPB	Upstream Bio	$2.85M	$773.00K
NTLA	Intellia Therapeutics	-	$7.66M
PHVS	Pharvaris	-	-
SYRE	Spyre Therapeutics	-	-
TRVI	Trevi Therapeutics	-	-
MAZE	Maze Therapeutics	-	-
ZYME	Zymeworks	$-27.11M	-

BCRX Revenue FAQ

What is BioCryst Pharmaceuticals’s yearly revenue?

BioCryst Pharmaceuticals's yearly revenue for 2025 was $874.84M, representing an increase of 94.10% compared to 2024. The company's yearly revenue for 2024 was $450.71M, representing an increase of 36.00% compared to 2023. BCRX's yearly revenue for 2023 was $331.41M, representing an increase of 22.37% compared to 2022.

What is BioCryst Pharmaceuticals’s quarterly revenue?

BioCryst Pharmaceuticals's quarterly revenue for Q2 2026 was $218.25M, a 39.53% increase from the previous quarter (Q1 2026), and a 33.61% increase year-over-year (Q2 2025). The company's quarterly revenue for Q1 2026 was $156.41M, a -61.53% decrease from the previous quarter (Q4 2025), and a 7.48% increase year-over-year (Q1 2025). BCRX's quarterly revenue for Q4 2025 was $406.56M, a 155.06% increase from the previous quarter (Q3 2025), and a 209.09% increase year-over-year (Q4 2024).

What is BioCryst Pharmaceuticals’s revenue growth rate?

BioCryst Pharmaceuticals's revenue growth rate for the last 3 years (2023-2025) was 163.97%, and for the last 5 years (2021-2025) was 456.62%.

What are BioCryst Pharmaceuticals’s revenue streams?

BioCryst Pharmaceuticals's revenue streams in c 25 are Collaborative And Other Research And Development, Product, and License. Collaborative And Other Research And Development generated $7.71M in revenue, accounting 0.88% of the company's total revenue, down -4.20% year-over-year. Product generated $623.15M in revenue, accounting 71.23% of the company's total revenue, up 40.77% year-over-year. License generated $243.98M in revenue, accounting 27.89% of the company's total revenue

What is BioCryst Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of BioCryst Pharmaceuticals was Product. This segment made a revenue of $623.15M, representing 71.23% of the company's total revenue.